Skip to content

Spinal Bupivacaine/Morphine in Laparoscopic Gastro-intestinal Surgery

Spinal Bupivacaine/Morphine in Laparoscopic Gastro-intestinal Surgery

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02284282
Acronym
Salmon
Enrollment
56
Registered
2014-11-06
Start date
2014-08-31
Completion date
2016-11-30
Last updated
2018-08-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal Bupivacaine/Morphine in Laparoscopic Surgery

Keywords

Spinal Morphine, Laparoscopic GI-surgery, Post-operative pain

Brief summary

The objective of this study is to determine if a single spinal shot of morphine can decrease post-operative opioid-use, and thereby decrease opioid side-effects and lead to a quicker recovery after surgery.

Detailed description

We expect that in laparoscopic gastro-intestinal surgery, a single shot spinal with bupicavaine/morphine will result in a better analgesia in hte first 48 hours. Herby the patients will require less systemic opioids, which will decrease the side-effects. Furthermore, we expect the patients to recover quicker and show an earlier mobilisation and a shorter hospital stay. The objective of this study is to determine if a single spinal shot of morphine can decrease post-operative opioid-use, and thereby decrease opioid side-effects and lead to a quicker recovery after surgery.

Interventions

DRUGSpinal injection bupivacaine/morphine

Spinal injection bupivacaine/morphine in laparoscopic surgery

DRUGsubcutaneum injection lidocaine

placebo injection

Sponsors

Maasstad Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Laparoscopic Gastro-intestinal surgery

Exclusion criteria

* Bariatric surgery, gastric surgery, rectal surgery, kidney failure, aorta-valve stenosis, coagulation disorders, emergency surgery

Design outcomes

Primary

MeasureTime frame
Duration of hospital stayfirst 48 hours

Secondary

MeasureTime frame
patient-satisfactory on a 4-point scale120 hours/ 5 days
the occurence of side-effects (nausea, pruritus, drowsiness)120 hours/ 5 days
time to mobilisation120 hours/ 5 days
use of piritramide by PCIA-pump in mg48 hours
abdominal compliance during laparoscopy in L/mmHgThe compliance will be measured for the duration of the surgery, an expected average of 2 hours.
Difficulty of surgeryThe difficulty of surgery will be measured for the duration of the surgery, an expected average of 2 hours
time to bowel movement120 hours/ 5 days

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 25, 2026